BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $KPTIQ readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT02227251-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:~Selinexor readout (P2) · Karyopharm Therapeutics Inc $KPTIQ
DESCRIPTION:Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffus
 e Large B-Cell Lymphoma (DLBCL)\n\nPrimary completion date: 2026-12 (estim
 ated) — month only\, shown on the 1st\nOriginally planned: 2016-07 (+125
 .0 months)\nPhase 2 · Oncology · Diffuse Large B-cell Lymphoma\nEnrollme
 nt: 244 · Sites: 175\n\nPrimary completion = last participant's primary-e
 ndpoint data collected\; topline results usually follow weeks to months la
 ter. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps
 ://datacutoff.com/radar.html?nct=NCT02227251\nhttps://clinicaltrials.gov/s
 tudy/NCT02227251
URL:https://datacutoff.com/radar.html?nct=NCT02227251
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04442022-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:~Selinexor (combination therapy) readout (P2/3) · Karyopharm Thera
 peutics Inc $KPTIQ
DESCRIPTION:A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP)
  With or Without Selinexor in Patients With Relapsed/Refractory Diffuse La
 rge B-cell Lymphoma\n\nPrimary completion date: 2026-12 (estimated) — mo
 nth only\, shown on the 1st\nOriginally planned: 2025-08 (+16.0 months)\nP
 hase 2/3 · Oncology · Relapsed/Refractory Diffuse Large B-cell Lymphoma\
 nEnrollment: 501 · Sites: 38\n\nPrimary completion = last participant's p
 rimary-endpoint data collected\; topline results usually follow weeks to m
 onths later. Sponsor-reported\, often an estimate. Not investment advice.\
 n\nhttps://datacutoff.com/radar.html?nct=NCT04442022\nhttps://clinicaltria
 ls.gov/study/NCT04442022
URL:https://datacutoff.com/radar.html?nct=NCT04442022
CATEGORIES:Oncology,Phase 2/3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05980806-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:~SENTRY-2 readout (P2) · Karyopharm Therapeutics Inc $KPTIQ
DESCRIPTION:A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor
 -naïve Myelofibrosis and Moderate Thrombocytopenia\n\nPrimary completion 
 date: 2027-06 (estimated) — month only\, shown on the 1st\nOriginally pl
 anned: 2026-04 (+14.0 months)\nPhase 2 · Cardio-Met · Myelofibrosis\, Mo
 derate Thrombocytopenia\, Mild Thrombocytopenia\nEnrollment: 58 · Sites: 
 70\n\nPrimary completion = last participant's primary-endpoint data collec
 ted\; topline results usually follow weeks to months later. Sponsor-report
 ed\, often an estimate. Not investment advice.\n\nhttps://datacutoff.com/r
 adar.html?nct=NCT05980806\nhttps://clinicaltrials.gov/study/NCT05980806
URL:https://datacutoff.com/radar.html?nct=NCT05980806
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
